X0202 SCHEDULE 13G/A 0001831942-25-000022 0001831942 XXXXXXXX LIVE 1 Common stock, $0.0001 par value per share 6/30/2026 0001833214 SAB Biotherapeutics, Inc. 78397T202 777 W 41st St Suite 401 Miami Beach FL 33140 Rule 13d-1(c) Commodore Capital LP DE 0.00 8948170.00 0.00 8948170.00 8948170.00 9.9 IA PN Commodore Capital Master LP E9 0.00 8948170.00 0.00 8948170.00 8948170.00 9.9 PN Robert Egen Atkinson X1 0.00 8948170.00 0.00 8948170.00 8948170.00 9.9 HC IN Michael Kramarz X1 0.00 8948170.00 0.00 8948170.00 8948170.00 9.9 HC IN SAB Biotherapeutics, Inc. 777 W 41st St, Suite 401, Miami Beach, FLORIDA, 33140. Commodore Capital LP Commodore Capital Master LP Robert Egen Atkinson Michael Kramarz Each a "Filer." The address for Commodore Capital LP, Robert Egen Atkinson, and Michael Kramarz is 444 Madison Avenue, Floor 35, New York, NY 10022. The address for Commodore Capital Master LP is c/o Maples Corporate Services Limited, Ugland House, South Church Street, PO Box 309, Grand Cayman KY1-1104, Cayman Islands. See Item 4 of the cover page for each Filer. Y See Item 9 of the cover page for each Filer. This report on Schedule 13G is being filed by Commodore Capital LP (the "Firm"), Commodore Capital Master LP ("Commodore Master"), Michael Kramarz, and Robert Egen Atkinson. The Firm is the investment manager to Commodore Master. As of June 30, 2026, the Firm may be deemed to beneficially own an aggregate of 8,948,170 shares of Common stock, $0.0001 par value per share (the "Common Stock"), consisting of (i) 2,870,000 shares of Common Stock (ii) 5,946,400 shares of Common Stock issuable upon the conversion of Series B Preferred Stock (the "Series B Preferred Stock"), and (iii) 131,770 shares of Common Stock issuable upon the conversion of Series B Preferred Stock underlying certain enrollment warrants (the ?Tranche 1 Warrants") of SAB Biotherapeutics, Inc. (the "Issuer"). The Series B Preferred Stock and the Tranche 1 Warrants are subject to a beneficial ownership limitation of 9.99% (the "Beneficial Ownership Limitation"). The foregoing excludes (i) 11,288,230 shares of the Tranche 1 Warrants, and (ii) 5,710,000 shares of Common Stock issuable upon the conversion of Series B Preferred Stock underlying certain release warrants (the "Tranche 2 Warrants"). The Tranche 1 Warrants and Tranche 2 Warrants are subject to the Beneficial Ownership Limitation. The Firm, as the investment manager to Commodore Master, may be deemed to beneficially own these securities. Michael Kramarz and Robert Egen Atkinson are the managing partners of the Firm and exercise investment discretion with respect to these securities. Ownership percentages are based on 83,493,068 Common Stock reported as issued and outstanding as of June 30, 2026 in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2026, plus (i) 5,946,400 Series B Preferred Stock, and (ii) 131,770 shares of the Tranche 1 Warrants . See Item 11 of the cover page for each Filer. See Item 5 of the cover page for each Filer. See Item 6 of the cover page for each Filer. See Item 7 of the cover page for each Filer. See Item 8 of the cover page for each Filer. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. Exhibit 1: Joint Filing Agreement Commodore Capital LP Michael Kramarz 08/14/2026 Commodore Capital Master LP Michael Kramarz 08/14/2026 Robert Egen Atkinson Robert Egen Atkinson 08/14/2026 Michael Kramarz Michael Kramarz 08/14/2026